摘要
目的:观察川芎嗪注射液和生脉注射液联合西药治疗慢性肺源性心脏病患者的临床疗效。方法:按随机数字表法将符合标准的134例患者分为治疗组和对照组,其中治疗组68例,对照组66例,对照组采用常规西医治疗,治疗组在对照组基础上加用川芎嗪注射液和生脉注射液治疗。结果:治疗组痊愈3例,痊愈率4.41%,显效31例,显效率45.59%,愈显率50.00%,总有效率92.65%。对照组痊愈1例,痊愈率1.51%,显效17例,显效率25.76%,愈显率27.33%,总有效率83.33%。两组比较,痊愈率差异无统计学意义,但愈显率和总有效率差异均有统计学意义(P<0.05)。治疗组患者咳嗽、呼吸困难和啰音减轻时间,以及每日排痰量与对照组比较,差异均有统计学意义(P<0.05)。两组患者心功能较治疗前均有所改善,与本组治疗前比较(P<0.05,治疗组与对照组比较(P<0.05)。两组患者右房压(Right Atrial Pressure,RAP)、右室压(Right Ventricular Pressure,RVP)和平均肺动脉压(mean Pulmonary Arterial Pressure,mPAP)较治疗前均有所改善,治疗组RVP和mPAP与对照组比较,差异有统计学意义(P<0.05),RAP差异无统计学意义(P>0.05)。未发现川芎嗪和生脉注射液的明显不良反应。结论:川芎嗪注射液和生脉注射液联合西药治疗慢性肺源性心脏病安全可靠,疗效优于单纯西药治疗。
Objective：To observe clinical effects of Ligustrazine Injection and Shengmai Injection combined with western medicine in the treatment of patients with chronic pulmonary heart disease .Methods：A total of 134 patients were randomized into observation and con-trol groups, 68 cases, 66 cases respectively .Control group was treated with conventional western medicine , the observation Group were treated with ligustrazine Injection and Shengmai Injection in addition .Results：Three patients in observation Group recovered , curative rate=4.41%, 31 patients improved , effective rate=45.59 %, responded rate=50%, total effective rate=92.65 %.1 patients in control Group recovered, curative rate =1.51%, 17 patients improved, effective rate=25.76%, responded rate=27.33%, total ef-fective rate=83.33%.Recovery rates were not significantly different between 2 groups （P〉0.05）, responded rate and total effective rates were significantly different （P〈0.05）.Observation group was significantly better at reducing cough , difficult breathing, heady sound, daily sputum volume compared with the control group （P〈0.05）.Both groups improved significantly after treatment in terms of heart functions, right atrial pressure （RAP）, right ventricular pressure （RVP） and mean pulmonary arterial pressure （mPAP）.RVP and mPAP improvements in observation group were significantly different than those of the control group （P〈0.05） No significant ad-verse reaction of Ligustrazine and Shengmai Injection was reported .Conclusion：Ligustrazine hydrochloride Injection and Shengmai In-jection combined with western medicine is safe and effective treatment for chronic pulmonary heart disease , better than using western medicine alone .
出处
《世界中医药》
CAS
2013年第11期1320-1322,共3页
World Chinese Medicine
关键词
川芎嗪注射液
生脉注射液
慢性肺源性心脏病
气阴两虚
痰瘀互结
Ligustrazine Injection
Shengmai Injection
Chronic pulmonary heart disease
Deficiency of both Qi and Yin
Stagnationof phlegm and blood
